Advanced search
Publication Cover
Future Oncology Volume 17, 2021 - Issue 30
Submit an article Journal homepage
5,018
Views
8
CrossRef citations to date
0
Altmetric
Plain Language Summary of Publication

A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer

Aditya Bardia1 Massachusetts General Hospital Cancer Center,Harvard Medical School,Boston, MA, USAView further author information
,
Sara A Hurvitz2 University of California, Los Angeles,Jonsson Comprehensive Cancer Center,Los Angeles, CA, USAView further author information
,
Hope S Rugo3 University of California, San Francisco,Helen Diller Family Comprehensive Cancer Center,San Francisco, CA, USAView further author information
,
Adam Brufsky4 Magee-Women’s Hospital and the Hillman Cancer Center,University of Pittsburgh Medical Center,Pittsburgh, PA, USAView further author information
,
Javier Cortes5 International Breast Cancer Center (IBCC),Quiron Group,Barcelona, SpainView further author information
,
Sibylle Loibl6 Department of Medicine and Research,Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus,Frankfurt, GermanyView further author information
,
M Piccart7 Institut Jules Bordet,Université libre de Bruxelles,Brussels, BelgiumView further author information
,
Janice Cowden8 Patient authorView further author information
,
Patty Spears8 Patient author;9 University of North Carolina Lineberger Comprehensive Cancer Center,Chapel Hill, NC, USAView further author information
&
Lisa A Carey10 Department of Medicine – Division of Hematology/Oncology,University of North Carolina Lineberger Comprehensive Cancer Center,Chapel Hill, NC, USAView further author information
 show all
Pages 3911-3924 | Received 12 Jul 2021, Accepted 11 Aug 2021, Published online: 01 Sep 2021

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Louis J Gautier & Lana Shkak. (2022) Past, Present and Future Oncology: Welcome to Volume 18. Future Oncology 18:1, pages 1-5.
Read now

Articles from other publishers (7)

Jan H. Müller, Henning Plage, Sefer Elezkurtaj, Tim Mandelkow, Zhihao Huang, Magalie C. J. Lurati, Jonas B. Raedler, Nicolaus F. Debatin, Eik Vettorazzi, Henrik Samtleben, Sebastian Hofbauer, Kira Furlano, Jörg Neymeyer, Irena Goranova, Bernhard Ralla, Sarah Weinberger, David Horst, Florian Roßner, Simon Schallenberg, Andreas H. Marx, Margit Fisch, Michael Rink, Marcin Slojewski, Krystian Kaczmarek, Thorsten Ecke, Steffen Hallmann, Stefan Koch, Nico Adamini, Maximilian Lennartz, Sarah Minner, Ronald Simon, Guido Sauter, Henrik Zecha, Thorsten Schlomm & Elena Bady. (2024) Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas. Frontiers in Oncology 13.
Crossref
·阿不都克里木 古丽斯热. (2024) Research Progress of Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer. Advances in Clinical Medicine 14:01, pages 1801-1807.
Crossref
Linlin Lu, Zihe Niu, Zhujun Chao, Cuiping Fu, Kai Chen & Yaqin Shi. (2023) Exploring the therapeutic potential of ADC combination for triple-negative breast cancer. Cellular and Molecular Life Sciences 80:12.
Crossref
Jingran Luo, Xinxin Chang, Suri Yuqing Wang & Hongchuan Yu. (2023) The Role of Monoclonal Antibodies in Breast Cancer. Highlights in Science, Engineering and Technology 36, pages 598-607.
Crossref
Qianqian Zhang, Mingjie Zhang & Wenhui Wang. (2022) Construction of Shikonin-Loaded Mammaglobin-Modified Liposomes for Breast Cancer Targeted Therapy. Nano LIFE 12:04.
Crossref
Anna Marie Maier, Anna Hester, Nadia Harbeck & Rachel Würstlein. (2022) Therapie des triple-negativen Mammakarzinoms. InFo Hämatologie + Onkologie 25:9, pages 42-55.
Crossref
S. Michaleas, A. Moreno Oliver, J. Mueller-Berghaus, S.B. Sarac, M.E. van der Elst, S. Müller-Egert, H. Zander, H. Enzmann & F. Pignatti. (2022) The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer. ESMO Open 7:3, pages 100497.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.